DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Razadyne (Galantamine Hydrobromide) - Summary



RAZADYNEtm ER/RAZADYNEtm (galantamine hydrobromide) is galantamine hydrobromide, a reversible, competitive acetylcholinesterase inhibitor.

RAZADYNEtm ER/RAZADYNEtm (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

See all Razadyne indications & dosage >>


Media Articles Related to Razadyne (Galantamine)

Alzheimer's Disease
Source: MedicineNet Immunizations Specialty [2017.06.01]
Title: Alzheimer's Disease
Category: Symptoms and Signs
Created: 8/5/2014 12:00:00 AM
Last Editorial Review: 6/1/2017 12:00:00 AM

Dementia, Alzheimer's Disease, and Aging Brains
Source: MedicineNet Hydrocephalus Specialty [2016.08.01]
Title: Dementia, Alzheimer's Disease, and Aging Brains
Category: Slideshows
Created: 12/3/2009 10:07:00 AM
Last Editorial Review: 8/1/2016 12:00:00 AM

Alzheimer's Disease Symptoms & Early Diagnosis
Source: MedicineNet memantine Specialty [2016.07.27]
Title: Alzheimer's Disease Symptoms & Early Diagnosis
Category: Slideshows
Created: 9/21/2015 12:00:00 AM
Last Editorial Review: 7/27/2016 12:00:00 AM

Caring for Someone With Alzheimer's Disease
Source: MedicineNet memantine Specialty [2016.05.16]
Title: Caring for Someone With Alzheimer's Disease
Category: Slideshows
Created: 2/16/2010 2:51:00 PM
Last Editorial Review: 5/16/2016 12:00:00 AM

7 Alzheimer's Disease Stages and Symptoms
Source: MedicineNet Advance Medical Directives Specialty [2016.05.12]
Title: 7 Alzheimer's Disease Stages and Symptoms
Category: Diseases and Conditions
Created: 7/30/2014 12:00:00 AM
Last Editorial Review: 5/12/2016 12:00:00 AM

more news >>

Published Studies Related to Razadyne (Galantamine)

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2014]
rivastigmine, and memantine for the treatment of AD... CONCLUSIONS: Cholinesterase inhibitors and memantine are able to stabilize or

The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease. [2014]
The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far... Patients who show improvement of episodic memory function during the first 4 weeks of galantamine administration may be likely to particularly benefit from galantamine treatment.

Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.

Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.

more studies >>

Clinical Trials Related to Razadyne (Galantamine)

Effect of Galantamine on Smoking Abstinence [Completed]
This is a preliminary open-label study to determine whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt.

A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to demonstrate that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine.

Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) [Completed]
The purpose of the study is to find out if the plasma concentration of galantamine extended release is changed when BMS-708163 is administered at the same time.

Galantamine Effects on Cognitive Function in Abstinent Cocaine Users [Completed]
To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these effects may result in improved cognitive performance in a group of subjects known to have impaired performance in various cognitive tasks.

Galantamine Effects on Nicotine Responses in Smokers [Completed]
This will be a 2-4 week double-blind, placebo-controlled study. Twenty four male and female smokers will first have two 4-day treatment periods, in which they will be randomized to galantamine (8 mg/day) or placebo. These treatment periods will be separated by a 3 to 14 day washout period. During the first 3-days of each treatment period, smokers will have daily clinic visits, where they will receive study medications and any adverse effects from study medications will be monitored. Starting at 10 p. m. on Day 1 of each treatment period, subjects will refrain from smoking for approximately 2. 5 days, until the experimental session on Day 4. Compliance with non-smoking will be verified by CO levels < 10 ppm. During the experimental sessions, subjects will receive saline or 1. 0 mg/70 kg of nicotine intravenously in a random, double-blind manner. The sequence of nicotine treatments will be counterbalanced among subjects such that equal number of subjects will receive saline first or nicotine first. Following each saline and nicotine treatments, physiological, subjective and cognitive measurements will be obtained

more trials >>

Page last updated: 2017-06-01

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017